Siglec15 Predicts Bladder Cancer Therapy Response

A set of gene signatures positively correlated with the clinical response of an anti-PD-L1 agent (atezolizumab) in BLCA were collected from Mariathasan's study 27 (link). Twelve bladder cancer signatures that are specific to different molecular subtypes were collected from the study performed by the Bladder Cancer Molecular Taxonomy Group 19 (link). We also collected other therapeutic signatures, including oncogenic pathways that could shape a non-inflamed TME, targeted therapy-associated gene signatures, and gene signatures predicting radiotherapy responses (Table S9). The enrichment scores of these signatures were calculated using the GSVA R package 43 (link). Subsequently, it was noted that the mutation statuses of several critical genes, including RB1, ATM, ERBB2, ERCC2, and FANCC, were predictors of the response to neoadjuvant chemotherapy in BLCA 44 (link)-47 (link).
After comparing the differences in the values of the enrichment scores of therapeutic signatures and the mutation statuses of neoadjuvant chemotherapy predictors between Siglec15 groups, we could determine the role of Siglec15 in predicting the response to these therapies. Finally, the BLCA-related drug-target genes were screened using the Drugbank database (Table S10) 48 (link).